

CSD/BSE&NSE/CC/2024-25
January 15, 2025

To
The Manager
Department of Corporate Services
BSE Limited
25th Floor, P. J. Towers,
Dalal Street, Mumbai - 400 001

To
The Manager
Listing Department
National Stock Exchange of India Limited
Exchange Plaza, Bandra Kurla Complex
Bandra (E), Mumbai – 400 051

Scrip Code: 543064

Scrip Symbol: SUVENPHAR

Dear Sir/Madam,

Sub: Investor Presentation

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 please find attached herewith the Investor Presentation on JPMC Healthcare conference Jan 2025.

You are requested to take this information on records.

Thanking you.

Yours faithfully,
For **Suven Pharmaceuticals Limited**

Kundan Kumar Jha
Company Secretary, Compliance Officer and Head-Legal

Suven Pharmaceuticals Limited

Registered Office: # 215 Atrium, C Wing, 8th Floor, 819-821, Andheri Kurla Road, Chakala, Andheri East, Chakala Midc, Mumbai- 400093, Maharashtra, India
Tel: 91 22 61539999

Corporate Office: # 202, A-Wing, Galaxy Towers, Plot No.1, Hyderabad Knowledge City, TSIIC, Raidurg, Hyderabad - 500081 Telangana, India
Tel: 91 40 2354 9414 / 3311

Email: info@suvenpharm.com | Website: www.suvenpharm.com | CIN: L24299MH2018PLC422236



Suven Pharmaceuticals Ltd.

...Going Above and Beyond

Investor Presentation

JPMC Healthcare conference Jan 2025

Leading technology-led Innovator Focused Global CDMO

STRONG FINANCIAL TRACK-RECORD OVER 20+ YEARS

DEEP CUSTOMER RELATIONSHIPS WITH MARQUEE BIG PHARMA

EXTENSIVE DEPTH AND WIDTH OF CHEMISTRY CAPABILITIES

MULTIPLE ENGINES OF GROWTH

USD 315mn
Revenue LTM Sep'24*

Top 14/20
Global Innovator Relations

1000+
Projects Executed

Pharma CDMO
Speciality CDMO and API+

14 Plants, 6 R&D labs
regulatory approved

~37%
EBITDA margins#

16 commercial
Molecules
Suven+Cohance

510+
Scientists


ADC and Oligo
Niche Capabilities

Best ESG practices
EcoVadis silver

Note: * LTM Revenue Sep'24 Suven & Cohance combined + Sapala proforma + CY24E NJ Bio proforma, INR 84.4/USD
Last 5 year Avg ; Cohance Lifescience amalgamation under process

Journey of Platform: We have instrumented a USD 315mn Global CDMO player

Building a technology-led CDMO - Augmenting scale organically and inorganically






Our Technology Platforms are the key differentiators for us

We have built strong expertise in high growth segments and will continue to invest in these segments organically and inorganically

	Suvен + Cohance	Indian CDMOs			Global CDMOs		
		Peer 1	Peer 2	Peer 3	EU Peer 1	EU Peer 2	Chinese Peer
Specialized Technologies – Small Molecules							
HPAPI – Cytotoxic Drugs	✓✓✓	✓✓	✓✓	✓✓	✓✓✓		✓✓
Controlled Substance	✓✓						
Flow Chemistry	✓				✓✓✓		✓✓
Antibody-Drug Conjugates	✓✓✓		✓✓		✓✓✓		✓✓✓
PROTACs (Protein Degradеrs)	✓✓✓		✓				✓✓✓
Oligonucleotides and Amidites	✓✓				✓✓	✓✓✓	✓✓✓
Peptides	✓	✓✓	✓✓	✓		✓✓✓	✓✓✓
Fermentation		✓			✓✓		✓✓
Standard Small Molecules							
Discovery	✓						✓✓✓
Development	✓✓	✓	✓✓	✓	✓✓		✓✓✓
Manufacturing	✓✓	✓✓	✓✓	✓✓	✓✓		✓✓✓
Biologics/Large Molecules							
Monoclonal Antibodies and Recombinant Technology			✓✓	✓	✓✓✓		✓✓✓
Cell and Gene Therapy					✓✓✓		✓✓✓



Delivered 2x+ superior returns compared to peers



Note: 5 years average comparison with Domestic and International peers



Source: Industry financials

Foundation pillars in place for the Horizon 2 acceleration



On the back of its unique position Suven is well poised to be a leader in the Global CDMO space from India

Established a Leading Technology-led innovator focused Global CDMO in short period of time



Today

Revenue* = \$315Mn+
60%+ CDMO

FY30E

Revenue = \$1Bn+
80%+ CDMO

FY35E

Revenue = \$2Bn+
90%+ CDMO

Professionally managed team

Scale acquired in short span via business combinations

Global Presence added with NJ Bio



Niche capabilities in ADC and Oligo.
NJ Bio acquisition -integrated End to End CRDMO in ADC

..... Set to deliver long term sustainable secular growth

*LTM Revenue Sep'24 Suven & Cohance combined + Sapala proforma + CY24E NJ Bio proforma, INR 84.4/USD

Our Growth Engines – Pharma CDMO key driver


Small Molecules, ADCs, Oligonucleotides and Peptides constitute ~52% of New Drug Additions to the Global Preclinical and Clinical Pipeline in 2024¹



Source: 1 Citeline Pharmprojects, *Proforma basis subject to the proposed amalgamation of Cohance Lifesciences
% sales - LTM Revenue Sep'24 Suven & Cohance combined + Sapala proforma + CY24E NJ Bio proforma


Suven is present in the fast growing tech platforms of ADCs & Oligos

CDMO Market by Technology – Market Size and Projected Growth (2023-29)



Significant R&D investments in ADC and Oligos/mRNA in the clinical pipeline

Global Clinical Active Pipeline



R&D pipeline growth (CAGR)		2019-24
Peptides		2%
Nucleic Acids (Oligos/mRNA)		19%
Antibody-Drug Conjugates (ADC)		20%
Vaccines and Viral Vectors		8%
Cell and Gene Therapy		12%
Biologics- Proteins/Antibodies		6%
Small Molecules - General		4%
Overall Clinical Pipeline		6%

Pharmaceutical Drug R&D Trends

Surging Interest in Targeted Therapies and Genetic Treatment leading to uptake in ADCs, Nucleic Acids and Cell/Gene Therapies

Presence in small molecules, contributing **>50% of total addressable R&D pipeline** (incl. Oligos, ADCs)

Suven uniquely placed to achieve leadership position in the fast-growing ADC/XDC segment

Expanded ADC offerings to become an integrated End to End CRDMO post acquisition of NJ Bio

Our unique capabilities in ADCs and XDCs

End-to-end CRDMO Partner from Drug Discovery to Commercialization

Extensive Library of Payload-Linkers for Discovery based on biology of the ADC target from a library of **500+** Payload-Linkers

Integrated Service Offerings: across variety of standard and custom Payloads, Linkers, Analytical and Bioconjugation

Global leadership in Camptothecin payloads; supplying to **2 commercial ADCs;** leadership in **S-Trione** - a key intermediate in camptothecin derivatives


Uniquely positioned as a Pureplay Payload Supplier: covering **75%** of Payload market

Unique breadth of **XDC** and different payload capabilities – **Oligonucleotides, Radionuclides, Protein Degraders**

Capacity augmentation in **US & India;** Portfolio expansion in new **payloads and linker**

ADC/ XDC CDMO market to grow ~3x in next 5 years

Total ADC/XDC outsourcing Market excluding mABs



Oligonucleotides is the emerging modality

with fast growing and immense opportunity for higher market share gain

Amongst the few CDMOs globally, supplying complex building blocks for Oligonucleotides

Our Niche in Oligonucleotide segment

Capable of synthesizing a **spectrum of modified amidites and nucleosides** with excellent purity with high level of backward integration (15+ steps)

Diversified innovator customer (CDMO and Diagnostic) base with a strong Japan presence

Only supplier of Tricyclo-DNA Amidites in the world

Multi-kilo scale synthesis of wide variety of GalNAc compounds supplied to Innovators with highest purity profile.


Mastered the chemistry of conformationally constrained nucleic acids and supply to innovators

Capacity augmentation: Investing in a **cGMP facility** to enhance capacity and drive R&D growth

Forward integrating to oligonucleotide drug substance manufacturing

Oligonucleotides market to grow at 25%+ CAGR

Market Size (\$ bn)



Amidite and Galnac segments to grow **significantly faster** than oligonucleotides market itself

Nucleic acids & oligos vital for R&D in therapeutics, diagnostics, and synthetic biology.

- **Market Growth:** Moving from rare diseases to high prevalence chronic indications. Rising use in molecular diagnostics and clinical applications.
- **Increased Investments:** Pharma and Biotech driving expansion


ESG Aspirations

We have set multi-dimensional ESG goals for the next 5 years

Our achievement

-  **ISO 45001:2018** Occupational Health and Safety Management System
-  **Business continuity management System ISO 22301 : 2019**
-  **British safety council five-star certification**
-  **Silver in EcoVadis Sustainability assessment**
-  **Committed to Science Based Target initiative (SBTi)**

 **97% score in TFS audit**



ESG Profile

ESG report for FY 2023-24

To be achieved

-  **Gold in EcoVadis Sustainability assessment - 2025**
-  **Signing third party purchase agreement for renewable power for all the facilities**
-  **Pharmaceutical Supply Chain Initiative (PSCI) membership - 2025**

Contact Information

Cyndrella Carvalho, Head - Investor Relations
Suven Pharmaceuticals Ltd

Tel: +91 9823615656

Email: cyndrella.carvalho@suvenpharm.com


.....

Gavin Desa / Rishab Barar
CDR - India

Tel: +91 98206 37649/ +91 77770 35061

Email: gavin@cdr-india.com / rishab@cdr-india.com

.....



Thank You